Abstract | OBJECTIVE: METHODS: Serum anti-HBc levels in the immune tolerant (IT), immune clearance (IC), low replicative (LR), and HBeAg negative hepatitis (ENH) phases from 634 treatment-naïve CHB patients were measured and compared between phases and with other serum markers. RESULTS: Median serum anti-HBc levels were different between the phases of CHB. Serum anti-HBc level was highest in the ENH phase and lowest in the IT phase. Serum anti-HBc level correlated only with ALT in the IC phase (r = 0.248, p < 0.001). The area under the receiver operating characteristic curve (AUC) of anti-HBc at a cutoff value of 9.03 S/CO for differentiation of IT and IC phases was 0.689 (sensitivity 74.03%, specificity 60.23%). The AUC for differentiation of LR and ENH phases was 0.751 (sensitivity 68.32%, specificity 70.53%) at a cutoff value of 9.74 S/CO for anti-HBc. CONCLUSIONS: Serum anti-HBc levels were significantly different across different phases of CHB and were associated with hepatitis activities.
|
Authors | Jian Wang, Xiaomin Yan, Yuxin Chen, Yong Liu, Li Wang, Bei Jia, Guiyang Wang, Yali Xiong, Peixin Song, Weihua Wu, Juan Xia, Sufang Lu, Zhaoping Zhang, Rui Huang, Chao Wu |
Journal | Discovery medicine
(Discov Med)
Vol. 26
Issue 143
Pg. 119-125
(10 2018)
ISSN: 1944-7930 [Electronic] United States |
PMID | 30586535
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiviral Agents
- Biomarkers
- Hepatitis B Antibodies
- Hepatitis B Core Antigens
|
Topics |
- Adult
- Antiviral Agents
(therapeutic use)
- Biomarkers
(blood)
- Disease Progression
- Female
- Hepatitis B Antibodies
(blood)
- Hepatitis B Core Antigens
(immunology)
- Hepatitis B virus
(immunology)
- Hepatitis B, Chronic
(blood, diagnosis, drug therapy, pathology)
- Humans
- Male
- Middle Aged
- Sustained Virologic Response
- Viral Load
|